| Literature DB >> 31230854 |
M Hameed1, J E O'Connell2, S N Rogers3.
Abstract
The management of giant cell granulomas is challenging, and aggressive lesions have a high tendency to recur after enucleation alone. Based on assumptions regarding cell type and receptors, multiple pharmacological adjuncts have been used to manage them. We describe the use of denosumab, which was successfully used as a single method of treatment, suggesting that it may be a viable alternative or adjunct to operation on giant cell granulomas of the jaws. CrownEntities:
Keywords: Denosumab; Giant Cell Granuloma; Medication related osteonecrosis; Monoclonal Antibodies; Osteoclasts; RANKL; neo-ossification
Year: 2019 PMID: 31230854 DOI: 10.1016/j.bjoms.2019.05.023
Source DB: PubMed Journal: Br J Oral Maxillofac Surg ISSN: 0266-4356 Impact factor: 1.651